Immunomonitoring of Mold Invasive Infections

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorAssistance Publique - Hôpitaux de Paris

About this trial

Mold invasive infections are associated with an important mortality despite optimization of the antifungal treatment. In a few case reports, immune checkpoints inhibitors, initially developed for neoplastic diseases, have shown a potential beneficial effect in such devastating infections by restoring an efficient immune response. The investigators propose a longitudinal monitoring of the adaptative immune response, notably immune checkpoint expression on T cells, during mold invasive infections to help identify the patients who could benefit from the adjunction of immunotherapy and the optimal timing of such strategy.

Eligibility criteria

Qualifiers

Age ≥ 18 years

Mold invasive fungal infection: Aspergillus, Mucorales, Fusarium, Scedosporium

Proven or probable according to 2019 EORTC/MGS criteria modified by the adjunction of diabetes mellitus in the host criteria and Mucorales PCR in the microbiological criteria

Within 14 days of IFD diagnosis or

Disqualifiers

Bacterial co-infection in the last 14 days

Previous treatment with anti-PD1 antibodies

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

20 Participants
are grouped into 1 trial group

Sponsors and collaborators

Assistance Publique - Hôpitaux de Paris

Lead sponsor

URC-CIC Paris Descartes Necker Cochin

Collaborator